Molecular Design of Peptide-Fc Fusion Drugs.

BACKGROUND Peptide-Fc fusion drugs, also known as peptibodies, are a category of biological therapeutics in which the Fc region of an antibody is genetically fused to a peptide of interest. However, to develop such kind of drugs is laborious and expensive. Rational design is urgently needed. METHODS We summarized the key steps in peptide-Fc fusion technology and stressed the main computational resources, tools, and methods that had been used in the rational design of peptide-Fc fusion drugs. We also raised open questions about the computer-aided molecular design of peptide-Fc. RESULTS The design of peptibody consists of four steps. First, identify peptide leads from native ligands, biopanning, and computational design or prediction. Second, select the proper Fc region from different classes or subclasses of immunoglobulin. Third, fuse the peptide leads and Fc together properly. At last, evaluate the immunogenicity of the constructs. At each step, there are quite a few useful resources and computational tools. CONCLUSION Reviewing the molecular design of peptibody will certainly help make the transition from peptide leads to drugs on the market quicker and cheaper.

[1]  I. James,et al.  CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. , 2008, Journal of biotechnology.

[2]  John Yu,et al.  Structure-based design for binding peptides in anti-cancer therapy. , 2018, Biomaterials.

[3]  Matthias Dehmer,et al.  Computational prediction of therapeutic peptides based on graph index , 2017, J. Biomed. Informatics.

[4]  M. Bhide,et al.  An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction , 2016, Journal of immunology research.

[5]  J J de Soet,et al.  Design of a Peptibody Consisting of the Antimicrobial Peptide dhvar5 and a llama Variable Heavy‐chain Antibody Fragment , 2006, Chemical biology & drug design.

[6]  Gajendra P. S. Raghava,et al.  CPPsite 2.0: a repository of experimentally validated cell-penetrating peptides , 2015, Nucleic Acids Res..

[7]  Leslie R Evans,et al.  Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.

[8]  Ralf Hoffmann,et al.  The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor , 2013, Amino Acids.

[9]  Yanxin Huang,et al.  Phage Display Informatics , 2013, Comput. Math. Methods Medicine.

[10]  J. Greenbaum,et al.  Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.

[11]  Babak Bakhshinejad,et al.  Biased selection of propagation-related TUPs from phage display peptide libraries , 2017, Amino Acids.

[12]  Sindy K. Y. Tang,et al.  Diversity of Phage-Displayed Libraries of Peptides during Panning and Amplification , 2011, Molecules.

[13]  Leonard Moise,et al.  iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines , 2015, Human vaccines & immunotherapeutics.

[14]  Jian Huang,et al.  A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo , 2016, Scientific Reports.

[15]  Gajendra P. S. Raghava,et al.  Hemolytik: a database of experimentally determined hemolytic and non-hemolytic peptides , 2013, Nucleic Acids Res..

[16]  A. Gautam,et al.  THPdb: Database of FDA-approved peptide and protein therapeutics , 2017, PloS one.

[17]  Ralf Hoffmann,et al.  Design and development of a peptide-based adiponectin receptor agonist for cancer treatment , 2011, BMC biotechnology.

[18]  D. Baccanari,et al.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. , 1997, Science.

[19]  Jian Sun,et al.  A Novel BLyS Peptibody Down-Regulates B Cell and T Helper Cell Subsets In Vivo and Ameliorates Collagen-Induced Arthritis , 2016, Inflammation.

[20]  Gary K. Schwartz,et al.  Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma , 2015, Cancer Chemotherapy and Pharmacology.

[21]  Deborah Hix,et al.  The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..

[22]  E. Jáuregui,et al.  Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview. , 2017, Current protein & peptide science.

[23]  Ronald Levy,et al.  Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies , 2016, Proceedings of the National Academy of Sciences.

[24]  M. Scheinberg,et al.  Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser , 2016, Expert opinion on biological therapy.

[25]  I. Macdougall,et al.  Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise , 2016, Expert opinion on drug safety.

[26]  Gajendra P. S. Raghava,et al.  ParaPep: a web resource for experimentally validated antiparasitic peptide sequences and their structures , 2014, Database J. Biol. Databases Curation.

[27]  Jian Huang,et al.  Structural Characterization of a Recombinant Fusion Protein by Instrumental Analysis and Molecular Modeling , 2013, PloS one.

[28]  Benjamin Wu,et al.  Pharmacokinetics of Peptide-Fc fusion proteins. , 2014, Journal of pharmaceutical sciences.

[29]  Chao Yang,et al.  Biomacromolecular quantitative structure–activity relationship (BioQSAR): a proof-of-concept study on the modeling, prediction and interpretation of protein–protein binding affinity , 2013, Journal of Computer-Aided Molecular Design.

[30]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[31]  A. Saxena,et al.  Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life , 2016, Front. Immunol..

[32]  Janet L Nichol,et al.  AMG 531: An investigational thrombopoiesis‐stimulating peptibody , 2006, Pediatric blood & cancer.

[33]  Alan Stuckey,et al.  A Peptide-Fc Opsonin with Pan-Amyloid Reactivity , 2017, Front. Immunol..

[34]  Nir London,et al.  Can self‐inhibitory peptides be derived from the interfaces of globular protein–protein interactions? , 2010, Proteins.

[35]  Gajendra P. S. Raghava,et al.  AHTPDB: a comprehensive platform for analysis and presentation of antihypertensive peptides , 2014, Nucleic Acids Res..

[36]  Jian Huang,et al.  Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis , 2016, Journal of biomolecular structure & dynamics.

[37]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[38]  Qian Peng,et al.  Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth , 2016, Oncotarget.

[39]  Hiroshi Mamitsuka,et al.  Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools , 2011, Briefings Bioinform..

[40]  Bifang He,et al.  A novel peptide specifically binding to VEGF receptor suppresses angiogenesis in vitro and in vivo , 2017, Signal Transduction and Targeted Therapy.

[41]  Feng-Biao Guo,et al.  MimoDB: a New Repository for Mimotope Data Derived from Phage Display Technology , 2010, Molecules.

[42]  Ignace Vergote,et al.  Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. , 2016, Gynecologic oncology.

[43]  Davor Juretic,et al.  DADP: the database of anuran defense peptides , 2012, Bioinform..

[44]  Ralf Mikut,et al.  Use of Peptide Libraries for Identification and Optimization of Novel Antimicrobial Peptides. , 2016, Current topics in medicinal chemistry.

[45]  A. Newland,et al.  Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside , 2010, British journal of haematology.

[46]  Z. Altintas,et al.  Computational Design of Peptide Ligands for Ochratoxin A , 2013, Toxins.

[47]  Peter A. C. 't Hoen,et al.  Phd7faster: Predicting Clones Propagating Faster from the pH.D.-7 phage Display peptide Library , 2014, J. Bioinform. Comput. Biol..

[48]  Hui Ding,et al.  NIEluter: Predicting peptides eluted from HLA class I molecules. , 2015, Journal of immunological methods.

[49]  Chichi Huang,et al.  Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. , 2009, Current opinion in biotechnology.

[50]  Jolene L. Lau,et al.  Therapeutic peptides: Historical perspectives, current development trends, and future directions. , 2017, Bioorganic & medicinal chemistry.

[51]  Chao Yang,et al.  Computational peptidology: a new and promising approach to therapeutic peptide design. , 2013, Current medicinal chemistry.

[52]  Mouldy Sioud,et al.  Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells , 2015, Molecular therapy. Methods & clinical development.

[53]  Chao Yang,et al.  Self-Binding Peptides: Folding or Binding? , 2015, J. Chem. Inf. Model..

[54]  Sergey Lyskov,et al.  Peptiderive server: derive peptide inhibitors from protein–protein interactions , 2016, Nucleic Acids Res..

[55]  Jennifer G. Abelin,et al.  The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction , 2018, Proteomics.

[56]  Hui Ding,et al.  BDB: biopanning data bank , 2015, Nucleic Acids Res..

[57]  Duncan Patrick McGregor,et al.  Discovering and improving novel peptide therapeutics. , 2008, Current opinion in pharmacology.

[58]  Gajendra P. S. Raghava,et al.  CancerPPD: a database of anticancer peptides and proteins , 2014, Nucleic Acids Res..

[59]  Faiza Hanif Waghu,et al.  CAMPR3: a database on sequences, structures and signatures of antimicrobial peptides , 2015, Nucleic Acids Res..

[60]  Jian Sun,et al.  The comparison of BLyS-binding peptides from phage display library and computer-aided design on BLyS-TACI interaction. , 2015, International immunopharmacology.

[61]  E. Rasmussen,et al.  A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction , 2017, Clinical pharmacology and therapeutics.

[62]  Borut Strukelj,et al.  Phage Display: Selecting Straws Instead of a Needle from a Haystack , 2011, Molecules.

[63]  Peng Zhou,et al.  SABinder: A Web Service for Predicting Streptavidin-Binding Peptides , 2016, BioMed research international.

[64]  Peng Zhou,et al.  Epitope Mapping of Metuximab on CD147 Using Phage Display and Molecular Docking , 2013, Comput. Math. Methods Medicine.

[65]  Zuben E Sauna,et al.  Fc fusion as a platform technology: potential for modulating immunogenicity. , 2015, Trends in biotechnology.

[66]  P. Zhou,et al.  Specific noncovalent interactions at protein-ligand interface: implications for rational drug design. , 2012, Current medicinal chemistry.

[67]  Michael Przybylski,et al.  A synthetic camel anti-lysozyme peptide antibody (peptibody) with flexible loop structure identified by high-resolution affinity mass spectrometry. , 2006, Chemistry.

[68]  Xingzhen Lao,et al.  Computational resources and tools for antimicrobial peptides , 2017, Journal of peptide science : an official publication of the European Peptide Society.

[69]  Jian Sun,et al.  A novel BLyS antagonist peptide designed based on the 3-D complex structure of BCMA and BLyS. , 2006, Biochemical and biophysical research communications.

[70]  K. Chou,et al.  iACP: a sequence-based tool for identifying anticancer peptides , 2016, Oncotarget.

[71]  Hiroaki Suga,et al.  Exploring sequence space: harnessing chemical and biological diversity towards new peptide leads. , 2017, Current opinion in chemical biology.

[72]  Vineet K. Sharma,et al.  Prediction of anti-inflammatory proteins/peptides: an insilico approach , 2016, Journal of Translational Medicine.

[73]  Ning Li,et al.  PSBinder: A Web Service for Predicting Polystyrene Surface-Binding Peptides , 2017, BioMed research international.

[74]  Alan Stuckey,et al.  Preliminary characterization of a novel peptide-Fc-fusion construct for targeting amyloid deposits , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[75]  A. Scheen,et al.  Dulaglutide for the treatment of type 2 diabetes , 2017, Expert opinion on biological therapy.

[76]  Jamie K. Scott,et al.  The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. , 2005, Analytical biochemistry.

[77]  J. Salfeld,et al.  Isotype selection in antibody engineering , 2007, Nature Biotechnology.

[78]  Tom Boone,et al.  Peptibodies: A flexible alternative format to antibodies , 2012, mAbs.

[79]  Joost Schymkowitz,et al.  Computational design of peptide ligands. , 2011, Trends in biotechnology.

[80]  Bifang He,et al.  Computational Design of Antiangiogenic Peptibody by Fusing Human IgG1 Fc Fragment and HRH Peptide: Structural Modeling, Energetic Analysis, and Dynamics Simulation of Its Binding Potency to VEGF Receptor , 2018, International journal of biological sciences.

[81]  Ping Zhu,et al.  MimoDB 2.0: a mimotope database and beyond , 2011, Nucleic Acids Res..

[82]  Marco Cavaco,et al.  Peptibodies: An elegant solution for a long‐standing problem , 2018, Biopolymers.

[83]  Wei Chen,et al.  Prediction of cell-penetrating peptides with feature selection techniques. , 2016, Biochemical and biophysical research communications.

[84]  Aleksander Lenert,et al.  Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date , 2017, Drug design, development and therapy.

[85]  Ping Dai,et al.  Bioinformatics Resources and Tools for Phage Display , 2011, Molecules.

[86]  Feng-Biao Guo,et al.  SAROTUP: Scanner and Reporter of Target-Unrelated Peptides , 2010, Journal of biomedicine & biotechnology.

[87]  A. Bernkop‐Schnürch,et al.  Strategies to improve plasma half life time of peptide and protein drugs , 2006, Amino Acids.

[88]  Saravanan Vijayakumar,et al.  ACPP: A Web Server for Prediction and Design of Anti-cancer Peptides , 2014, International Journal of Peptide Research and Therapeutics.

[89]  Jian Huang,et al.  CED: a conformational epitope database , 2006, BMC Immunology.